spacer
home > ebr > winter 2009 > new frontiers for opioid drugs
PUBLICATIONS
European Biopharmaceutical Review

New Frontiers for Opioid Drugs

Although the psychological effects of opium were probably known to the ancient Babylonians over 6,000 years ago, it is welldocumented that extracts of the opium poppy Papaver somniferum have been used since the 3rd century BC to relieve pain, promote sleep and induce euphoria. Yet the use of opiates to treat diarrhoea and dysentery, perhaps surprisingly, appears to predate its other therapeutic applications, highlighting the important role of opioid signalling in the gastrointestinal (GI) system. In recent years, interest in the GI effects of opioids has been reignited by the development of selective agonists and antagonists and improved delivery methods that target opioid receptors in the GI system.

Crude opium contains more than 20 alkaloids. The main alkaloid constituent of opium, subsequently shown to be almost entirely responsible for the analgesic action, was isolated by Serturner in 1803 and given the name morphia, after Morpheus, the Greek god of dreams. In the intervening 200 years, our understanding of how opioid drugs work and their therapeutic potential has developed enormously.

This was primarily due to our current knowledge of the physiological and pathophysiological roles of opioid receptors, a great deal of which has arisen from in vitro pharmacology experiments using mammalian tissues. For the foreseeable future, opioid drugs will be important analgesics and anti-motility agents. However, other therapeutic uses are emerging as we begin to understand how opioid receptors influence sensation, inflammation, growth, secretion and absorption within the GI tract.

OPIOID RECEPTORS IN THE GASTROINTESTINAL TRACT

It is now well-established that there are three ‘classical’ types of opioid receptor, mu-, delta- and kappa-, and the genes encoding these receptors have been cloned. In 1994, cDNA encoding a fourth opioid receptor was identified...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
David Bunton is co-founder and Chief Operating Officer of Biopta Ltd, a human tissue based CRO that specialises in functional assays in ex vivo human tissues. David has a PhD in pharmacology, over eight years’ experience of preclinical contract research and developed the PM-1 instrument for the study of isolated tissues. Prior to founding Biopta, David was a Lecturer in Physiology at Glasgow Caledonian University.

Lee Rankin is a Study Director at Biopta Ltd. Lee has a Masters in Pharmacology from the University of Glasgow and has over five years’ experience of in vitro assays using human gastrointestinal tissues to study the effects of a range of drugs, in particular opioids.

Alistair Corbett is a Senior Lecturer at Glasgow Caledonian University, where his research focuses on the role of endogenous opioid peptides in intestinal disorders. Following his PhD at the University of Glasgow, Alistair joined Professor Hans Kosterlitz (codiscoverer of the enkephalins, the first endogenous opioid peptides) at the University of Aberdeen, producing more than 30 full publications and many conference presentations on various aspects of opioid physiology, pharmacology and chemistry.

spacer
David Bunton
spacer
spacer
spacer
Lee Rankin
spacer
spacer
spacer
Alistair Corbett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI and CSP Technologies, Inc. Announce Strategic Collaboration for Breakthrough Activ-BlisterTM Solutions

Philadelphia, PA & Auburn, AL – September 17, 2018 PCI Pharma Services (PCI), a full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global healthcare industry, is pleased to announce its exclusive collaboration agreement with CSP Technologies, Inc. for U.S. clinical trials and stability testing utilizing Activ-BlisterTM packaging solutions, which help protect and promote speed-to-market for pharmaceutical and medical device products with heightened susceptibility to moisture and gases, especially oxygen.
More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement